Results from this study can provide a framework for other types of cancer that overexpress HER2 or undergo first-line radiation therapy (i.e., gastric and lung cancer) to increase therapeutic efficacy, reduce tumor burden, and provide clinically relevant noninvasive monitoring approaches of the tumor microenvironment to help guide clinical decision making in cancer. Here, ERBB2 is linked to cancer.